Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion). HTA ID: 20048
Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion) is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
| NCPE Assessment Process | Ongoing |
| Rapid review commissioned | 28/10/2020 |
| Rapid review completed | 18/12/2020 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amikacin sulfate (Arikayce® liposomal nebuliser dispersion (ALND) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies |
| Full pharmacoeconomic assessment commissioned by HSE | 04/01/2022 |
| Full HTA Submission received from Applicant | 01/04/2022 |
| Current Status | Full HTA submission received from Applicant |